ArticleClinical and translational medicine2022

Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.

Cunte Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.